ADCT · ADC Therapeutics
AI read · Good for ADCT
The AI's read
ADCT completed LOTIS 7 enrollment and says the Zynlonta plus glofitamab combo shows compelling second-line DLBCL data. The company also cut 17% of staff, saved $10m annually, and holds cash into 2028, so commercialization is plausible. The market barely reacted, down 1.7% and RSI ~51, so the call didn’t trigger a decisive re-rate. That leaves room for upside if the ASH abstract and regulatory conversations land positively. We lean bullish because the clinical readout plus a multi-year cash runway creates asymmetric upside versus downside. Conviction is tempered by the LOTIS 5 FDA concerns and remaining regulatory risk.